 |
 |

COMMENTS AND OPINIONS
Medications Impair Kidney Function in Stroke Population—Reply
Bruce Ovbiagele, MD
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In reply
I thank Dr Kittisupamongkol for the interest in my study. I am unclear about the nature of the comment in the letter pertaining to the metabolic syndrome. The point about the influence of certain medications traditionally used in vascular risk reduction on kidney function is well taken, but I have to disagree with the notion that such effects are necessarily deleterious. Indeed, most patients with chronic kidney disease (CKD) tend to die of cardiovascular causes and not progression to end-stage renal disease. Thus, it is generally recommended that health care practitioners aim to lower vascular risk, a strategy that often requires the use of several widely prescribed medications such as statins, antiplatelet therapies, and modulators of the rennin-angiotensin system.1 Rennin-angiotensin system modulators such as angiotensin-converting enzyme inhibitors may actually improve clinical outcomes in many patients with CKD.2-4 Other studies have shown no signs of toxic . . . [Full Text of this Article] AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Impairment in Glomerular Filtration Rate or Glomerular Filtration Barrier and Occurrence of Stroke
Bruce Ovbiagele
Arch Neurol. 2008;65(7):934-938.
ABSTRACT
| FULL TEXT
RELATED LETTER
Medications Impair Kidney Function in Stroke Population
Weekitt Kittisupamongkol
Arch Neurol. 2009;66(3):416.
EXTRACT
| FULL TEXT
|